enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. List of largest pharmaceutical mergers and acquisitions

    en.wikipedia.org/wiki/List_of_largest...

    Pfizer: Astra Zeneca: 99 127 AstraZeneca claimed the deal undervalued the company. [16] 5 1999 Pfizer: Warner–Lambert: 82.4 151 Pfizer made a hostile bid, just after the announcement of a $72 billion deal with Wyeth, the eventual purchase price would be in excess of $90 billion. [17] [18] [19] 6 1999 Wyeth: Warner–Lambert: 72 132

  3. Hospira - Wikipedia

    en.wikipedia.org/wiki/Hospira

    Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.It had approximately 19,000 employees. [1] Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, [2] manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication ...

  4. Pfizer Eyes $20 Billion Revenue From Acquisitions Amid ... - AOL

    www.aol.com/pfizer-eyes-20-billion-revenue...

    On the cost side, Pfizer achieved $4 billion in savings and announced an additional $1.5 billion in margin improvements. In R&D, leadership changed for the first time in 15 years,

  5. Viatris - Wikipedia

    en.wikipedia.org/wiki/Viatris

    Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania.The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

  6. Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4 - AOL

    www.aol.com/news/mylan-pfizers-upjohn-unit...

    The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

  7. Mylan - Wikipedia

    en.wikipedia.org/wiki/Mylan

    In January 2019, the FDA announced its approval of the company's Wixela Inhub, the first approved generic version of GlaxoSmithKline's Advair Diskus. [ 81 ] Merger with Pfizer's off-patent drug business and name change to Viatris

  8. The Oncology Bet Is Already Paying Off For Pfizer

    www.aol.com/oncology-bet-already-paying-off...

    While Pfizer already counts on oncology for boosting sales, Moderna’s sales are still made by the Covid shot, along with RSV one that brought $10 million in U.S. sales after gaining approval in May.

  9. Guidant - Wikipedia

    en.wikipedia.org/wiki/Guidant

    Abbott agreed to purchase $1.4 billion of Boston Scientific stock and pay $4.1 billion for Guidant's vascular intervention business upon completion of the merger. Without Abbott's financial assistance, it would have been unlikely that Boston Scientific could have produced the counteroffer.